Pharmaceutical

Top 10 Best-Selling Drugs in Q1 2025 Market Trend Keytruda Merck Semaglutide Novo Nordisk Discover the top 10 best-selling drugs of Q1 2025. GLP-1 drugs dominate, with semaglutide and tirzepatide leading growth. Oncology and autoimmune treatments face challenges amid rising competition and patent expirations.
Merck KGaA Advances Lupus Drug Enpatoran to Phase 3 Merck Biotech Merck KGaA advances its lupus drug enpatoran into phase 3 after positive phase 2 results in cutaneous lupus, despite setbacks in systemic lupus cohorts. The drug shows strong efficacy and a favorable safety profile.
Accropeutics' AC-201 TYK2/JAK1 Inhibitor Shows Strong Phase 2 Psoriasis Trial Results Biotech Accro Bioscience Accropeutics Accropeutics’ TYK2/JAK1 inhibitor AC-201 achieved positive phase 2 results in treating moderate to severe plaque psoriasis in China, showing strong efficacy and safety, with plans to accelerate clinical development.
France Funds OSE's €1.3M mRNA Therapy Project OSE Immunotherapeutics French biotech OSE Immunotherapeutics secures €1.3M government funding to lead HexARN project, advancing mRNA therapeutics for inflammatory diseases with partners Inside Therapeutics and University of Angers.
FDA Panel Supports Darzalex for Early Myeloma Darzalex Johnson&Johnson Biotech FDA Johnson & Johnson's Darzalex Faspro gains FDA advisory backing as a potential first treatment for high-risk smoldering multiple myeloma, despite concerns over trial design, patient selection, and long-term efficacy.
Moderna Delays Flu/COVID Combo Shot Filing Moderna Moderna has withdrawn its FDA application for the mRNA-1083 flu/COVID-19 combo vaccine after agency discussions, planning to resubmit later in 2025 with Phase III flu vaccine data amid shifting U.S. regulatory requirements.
SK Bioscience Wins Key Patent Battle SK Bioscience Pfizer SK Bioscience wins a key patent dispute against Pfizer in South Korea, enabling global exports of its 13-valent pneumococcal vaccine. The company plans expansion into Southeast Asia and Latin America while advancing next-gen vaccine R&D.
Pharma's $158B U.S. Manufacturing Surge Market Trend Eli Lilly Novartis Roche Regeneron Major pharmaceutical companies pledge $158 billion to U.S. manufacturing to sidestep tariff threats, funding facilities from California to North Carolina. Lilly, J&J, Novartis, Roche and Regeneron drive billions in reshoring investments, creating thousands of jobs.
BAFF-R CAR-T: CR 100% CAR-T Biotech PeproMene Bio's BAFF-R targeted CAR-T therapy PMB-CT01 shows 100% complete response in Phase 1 trials for B-cell lymphomas and leukemia, offering promising, durable results with manageable safety.
Global Biopharma Layoffs May 2025 Layoffs Stay updated on recent global biopharma layoffs in May 2025 with Guideview. Learn about job cuts, restructuring plans, and the latest industry developments across leading biotech and pharma companies.